Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 07/02/2008 - (DGNews)
    Silent Cerebral Infarction Reported in 10% of Healthy People - (DGNews)
    TopAbstracts in Hypertension 06/25/2008 - (DGNews)
    Normal Range of Albumin Too Low to Predict Hypertension - (DGNews)
    Home Hypertension Monitoring Plus Web-Based Pharmacy Care Helps Improve Blood Pressure Control - (DGNews)

    News archive

     Recent webcasts/CME - Hypertension
    • Improving Outcomes in Hypertension and Congestive Heart Failure: Focus on New Generation ß-Blockers
    • Tackling a Silent Threat: Implications and Management of Peripheral Artery Disease
    • Peripheral Artery Disease: A Highly Prevalent Disease Remains Underdiagnosed and Undertreated
    • Pharmacotherapeutic Treatments for Hypertension Complicated with Proteinuria
      Hypertension in the Elderly

      Webcasts/CME archive

       Recent cases - Hypertension
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion
        A Case of Hyperreninemic Hypertension with Bilateral Positive Captopril Renography but without Renovascular Stenosis
        Unusual Sequel of Successful Laparoscopic Unilateral Adrenalectomy in a Hypertensive Adolescent

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Investigative Anti-Impotence Drug Appears Safe With Antihypertensive Medications: Presented at ACC

        By Ed Susman

        CHICAGO, IL -- April 4, 2003 -- Analysis of several key studies of the investigational anti-impotence drug vardenafil indicates that the medication will be safe with antihypertension treatments.

        Researchers presented their findings here March 31st at the 52nd Annual Scientific Session of the American College of Cardiology.

        "However, patients cannot use vardenafil with nitrates," said Robert Kloner, MD, of Good Samaritan Hospital, Los Angeles, California. "The warning that is in place for sildenafil is also in effect for this new drug."

        He said nitrates and the phosphodiesterase-5 inhibitors appear to exert a synergistic effect on blood pressure that can cause severe symptoms, including death.

        "What we can say is that vardenafil may be associated with small, transient variations in blood pressure and heart rate relative to placebo. Vardenafil exhibited a favorable cardiovascular safety profile with the overall incidence of cardiovascular-related events similar to placebo."

        The serious adverse events in the analysis, which included studies involving 1,199 placebo patients and 2,203 men on vardenafil, amounted to about 2.5% in each group. One death occurred in the placebo patient group; no deaths occurred among patients on vardenafil. The patients were on study drugs from 12 to 26 weeks, depending on the study design.

        Co-author Harin Padma-Nathan, MD, of The Male Clinic, Beverly Hills, California, said hypertensive patients in the study were taking angiotensin-converting enzyme inhibitors, calcium antagonists, beta blockers, diuretics, alpha-blockers, and angiotensin receptor blockers. When the patients also took vardenafil, systolic blood pressures fell between 3 and 7 points and diastolic blood pressures fell between 2.6 and 5 points.

        About 4% of patients discontinued the drug because of adverse events, most often hypertension, tachycardia, palpitations, and peripheral edema.

        The study was sponsored by the Bayer Pharmaceutical Division, West Haven, Connecticut.


        [Study title: Cardiovascular Safety of Vardenafil in Patients Receiving Antihypertensive Medications: A Post-Hoc Analysis of Five Placebo-Controlled Clinical Trials. Abstract: 1133-148]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send